Tech Company Financing Transactions
CODA Biotherapeutics Funding Round
On 12/6/2021, CODA Biotherapeutics raised $28 million in funding from Pacira Pharmaceuticals, MPM Capital and Silicon Valley Bank.
Transaction Overview
Company Name
Announced On
12/6/2021
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$28,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The equity investment capital will help us progress our neuropathic pain therapies toward human clinical trials where we hope to demonstrate transformative results for patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 2nd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform for the treatment of many disorders and diseases. The company is using a revolutionary chemogenetics-based technology to modulate the activity of pathological cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Narachi
Vice President
Steven Dodson
VP - R & D
Orion Keifer
Browse more venture capital transactions:
Prev: 12/6/2021: P00LS venture capital transaction
Next: 12/6/2021: 100 Thieves venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record funding rounds that are announced publicly. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs